Recently public company Tarsus Pharmaceuticals Inc. unveiled positive data from a Phase IIb/III study in eyelash mites on 21 June for an antiparasitic medicine initially developed to prevent tick and flea infestation in domestic animals such as dogs. In an interview, Tarsus CEO Bobak Azamian explained that there is precedent in both antiparasitic and ophthalmic medicine to adapt compounds initially developed for animal health uses.
The Irvine, CA-based firm, which raised more than $100m in its initial public offering in October, said TP-03, an ophthalmic...








